



## COMPANY PROFILE

UPDATED January 9, 2009

*Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. We are focused on developing products addressing the large commercial opportunities within our core business areas: Gram-positive bacterial infections, and nicotine addiction.*

### VISION

Nabi Biopharmaceuticals' vision statement is, "To unlock the power of the human immune system to help people with serious, unmet medical needs."

### BUSINESS STRATEGY

Nabi Biopharmaceuticals is working to apply vaccine and antibody technologies to develop new products that address significant unmet medical needs. In order to advance pipeline technologies and build new commercial opportunities, we leverage cash and cash return from our operations, and seek partnering opportunities that will enhance our technology platform.

### STRATEGIC PLAN

To increase shareholder value and move our products forward in 2007, we formed two strategic business units, Nabi Biologics and Nabi Pharmaceuticals. On December 3, 2007, we completed the first step in the sale of the Biologics unit including Nabi-HB® and other plasma business assets, including Nabi's state-of-the-art plasma protein production plant and nine FDA-certified plasma collection centers across the U.S. The sale also includes certain of Nabi's Corporate Shared Services group assets, the company's Boca Raton, Florida headquarters and other facilities as well as the assumption of certain

liabilities. Biotest AG has submitted applications for manufacturing and sales and wholesale distribution with the U.S. Food and Drug Administration and the Florida Department of Health that, when issued, will enable Biotest to assume full manufacturing and sales operations in the United States. Until such licenses are issued, Nabi will continue to oversee day-to-day management and operations for the business unit and facilities that are subject to such licenses.

Nabi Biopharmaceuticals is now headquartered in Rockville, Maryland and will operate its Pharmaceuticals business unit from this location. The pharmaceuticals business unit has responsibility for our vaccine pipeline programs NicVAX® (Nicotine Conjugate Vaccine) and StaphVAX® -Pentavalent (Staphylococcal Polysaccharide Conjugate and Toxoid Vaccine). This unit will also support our milestone-related clinical obligations related to the sale of PhosLo® (calcium acetate).

### SIGNIFICANT MARKET OPPORTUNITIES

Nabi Biopharmaceuticals has a product pipeline focused on significant market opportunities where current treatment options are inadequate, such as drug-resistant Gram-positive infections and nicotine addiction.

### ANALYST COVERAGE

**Mark Schoenebaum, M.D.**  
Bear Stearns

**Cathy Reese**  
Boca Institutional Research Group  
(division of J Giordano Securities  
Group)

**Stephen Dunn**  
Dawson James

**Robert Wasserman**  
Jesup & Lamont Securities Corporation

**Lawrence B. Lappin**  
Hamed Khorsand  
Prime Executions, Inc.

**Joe Slavinsky, Ph.D.**  
Thomas Weisel Partners

### CONTACT INFORMATION

**Gregory L. Fries**  
Manager, Investor Relations and Corporate Communications  
**Nabi Biopharmaceuticals**  
12276 Wilkins Avenue, Rockville, MD 20852  
P: 301.255.6803 E: irpr@nabi.com, www.nabi.com

### MANAGEMENT TEAM

**Raafat Fahim, Ph.D.**  
President and Chief  
Executive Officer

**Paul Kessler, Ph.D.**  
Senior Vice President, Clinical,  
Medical and Regulatory Affairs

**Matthew Kalnik, Ph.D.**  
Vice President, Business  
Development and Project Management

**Ali E. Fattom, Ph.D.**  
Vice President, Research and  
Development